Lumance®
Intestinal health solution to lower medication and improve performance
Intestinal health is the most determining factor for animal health in general, herd performance, and eventually farm profitability.
Pathogenic bacteria can colonize the gastrointestinal tract and result in sub-clinical and clinical disease. Reduced feed intake and daily gain, inactivity, and decreased performance are all observed in animals with bacterial infections.
Low-quality feed
Livestock producers are often forced to use feed materials (carbohydrates, proteins, and oils) of lower quality. This means that animals are constantly challenged not only with changing diet compositions but also with feed quality. Both pause great risks for their health.
Stress
stress (both biotic and abiotic) often leads to health challenges and intestinal disorders and is linked with the ‘leaking gut’ syndrome. The end-product is subclinical inflammation which can cost up to 30% of the animal’s energy.
Restrictions of antibiotic and ZnO usage
Regulation, food safety, and animal welfare are setting up as well as new trends towards limitations or restrictions of antibiotic usage for disease treatment, medicated feed, zinc oxide, etc.
Lumance® offers a comprehensive INTESTINAL HEALTH MANAGEMENT program that achieves growth promotion with concomitant medication reduction by lowering gut inflammation, strengthening the intestinal integrity of the epithelium, and regulating beneficially the microbiota of the lumen by protecting against some key pathogens.
Intestinal Health & Medication Control
Lumance® is a proprietary complex technology which incorporates:
◉ The newest generation of butyrate for slow and targeted release throughout the gut
◉ Protection technologies to ensure that:
– Short Chain Fatty Acids,
– Medium Chain Fatty Acids,
– Essential Oils,
– Plant Extracts rich in polyphenols
Are actively delivered in the Gut and,
Can withstand pelleting and extrusion processes
Lumance® is an effective and powerful tool to reduce inflammation, promote villi growth, tighten the intestinal junction, and stabilize the microflora.
Lumance® - Product features and modes of action:
1. Reinforcing the gut integrity
Slow and targeted release of butyrate throughout the intestinal tract.
Butyrate:
◉ Provides energy to colonocytes enhancing gut development. Thus, it stimulates the growth of villi and micro-villi as it is their preferred energy source.
◉ Enhances the intestinal barrier by facilitating tight junction assembly.
◉ Reinforces the intestinal defense by:
– stimulating the release of Host Defense Peptides and
– inducing antimicrobial activity in intestinal macrophages in vivo and increasing resistance to enteropathogens, without triggering tissue-damaging inflammation
◉ Acts as an intestinal cell multi-mediator regulating multiple functions of gut cells and beyond, including gene expression, cell differentiation, gut tissue development, immune modulation, oxidative stress reduction, and diarrhea control.
◉ Reduces intestinal inflammation
2. Reducing gut inflammatory responses
The anti-inflammatory properties of butyric acid are complemented by selected plant extracts rich in alkaloids and essential oils found in the unique Lumance® Technology. Their efficacious anti-inflammatory and synergistic effects have been demonstrated both in vitro and in vivo.
a) In vitro inhibition of LPS induced inflammation in macrophage producing cell lines by Lumance® expressed as a reduction of Nitric Oxide,
b) Demonstration of the synergistic effect of Lumance®
c) In vivo demonstration of the anti-inflammatory effect of Lumance® (gene expression of the chicken Host Defense Peptide, β-defensin 9 - AvBD9)
3. Balancing the lumen and its gastrointestinal microbiota
Lumance® has been carefully designed to reduce the impact of key pathogens and support the growth of beneficial bacteria in the lumen. In vitro tests performed at the University of Ghent, Belgium revealed significant antipathogenic activity against key pathogens such as Salmonella Typhimurium (SL1344) and Clostridium perfringens (CP56) in a dose-response manner.
4. Protecting against Reactive Oxygen Species (ROS)
Butyrate stimulates endogenous glutathione release which is the most potent antioxidant within the animal’s metabolism. Importantly, Lumance® as explained previously meets a key requirement, and the esterified butyrate in its composition reaches the hindgut. In addition, the plant extracts and essential oils added in Lumance® have been selected for their antioxidant activity and oxidative stress inhibitory effect, which complements those exerted by butyrate (data not shown).
5. Proven slow and targeted release of butyric acid in the gut
For any externally supplied form of butyric acid to act, it is imperative that it reaches the hindgut. Lumance® has been tested in an advanced in-vitro model which mimics the digestion in the gastro-intestinal tract (stomach, duodenum, and hind-gut). The sophisticated three-step enzymatic incubation did prove that the esterified n-butyric acid within Lumance® a) by-passes the stomach with practically no losses, b) gets activated only at the duodenum level and, c) reaches the hind-gut.
6. Exerting a synergistic effect in the gut
The anti-inflammatory effect of Lumance® is superior to any of its single groups of components (fatty acids, plant extract, and essential oils). In fact, the anti-inflammatory activity of Lumance®; was increased by 25% (p<0.05) compared to the theoretical sum of its groups of components.
- Application & doses recommendation
- Finished Feed: 0.250 - 1.0 kg/t depending on species, challenge, and objective
- Calf milk replacer: min 1 ml/liter of milk
- Via drinking water: min 0.5 ml/liter of water
- Lumance® Application Table
The Synergistic effect of Lumance®
It is critical to developing cost-effective antibiotic alternative strategies to ensure the long-term sustainability of animal production. Dr. Alireza Khadem, Research & Technical Manager Poultry at Innovad® and Ph.D. researcher at the University of Ghent tested the anti-inflammatory activity of Lumance® and the effect of its three main ingredients (fatty acids, essential oils, and plant extracts) individually.
Better performance through a synergistic combined approach in broilers raised without antibiotics
Innovad® evaluated the in-vitro antibacterial activity of Lumance®. We then correlated the findings with a large-scale in-vivo trial which evaluated the ability of Lumance® to replace three different commercial feed additive products that were applied simultaneously to control Necrotic Enteritis in order to maintain performance, in the absence of antibiotic growth promoters.
Colibacillosis in layers
Colibacillosis, a syndrome caused by E. coli, is one of the most common infectious bacterial diseases of the layer industry. Inflammation resulting from either feed or disease is inversely related to growth and health. This technical Bulletin contains more information on this subject and a study performed with the University of Ghent on the anti-inflammatory effects of Lumance®.
Lumance®; enhances the intestinal barrier function and ameliorates barrier disruption
Stressors like pathogens and toxins increase gut permeability leading often to chronic inflammation and disease such as Necrotic Enteritis. Deoxynivalenol (DON) increases gut permeability and predisposes for Clostridium perfringens induced Necrotic Enteritis in broiler chickens. In other words, DON can replace coccidiosis (Eimeria) as a predisposing factor for NE. Transepithelial electrical resistance (TEER) is a widely accepted technique to measure the integrity of tight junction dynamics in cell culture models and the IPECJ-2 cell line is a well-established model for studying intestinal barrier functions. This article demonstrates that Lumance® enhances significantly the tight junctions even under bacterial enterotoxin (LPS) challenge in IPECJ-2 cells.
Prevention of necrotic enteritis in broiler chickens
Necrotic enteritis (NE) is a multifactorial disease, resulting in an important negative impact on the poultry industry due to decreased weight gain, increased mortality, worse feed conversion ratio, greater medication costs, and increased risk of contamination of poultry products for human consumption. This study a) evaluated the in-vitro antibacterial activity of Lumance® and b) correlated the findings with a large-scale the in-vivo trial that evaluated the ability of Lumance® to replace three commercial non-antibiotic feed additives used to control NE and maintain performance in the absence of antibiotic growth promoters.
Webinar: Controlling Chronic Inflammation With Feed Additives
- Quality assurance and certificates:
- FAVV – Belgian Federal Agency for the Safety of the Food Chain
- Feed Hygiene Legislation
- Feed Chain Alliance (GMP Animal Feed – Ovocom)
- FAMI-QS Certification
- Manufacturer:
